Elite Pharmaceuticals Inc (ELTP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Elite Pharmaceuticals Inc (ELTP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10080
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Elite Pharmaceuticals Inc (Elite) is a specialty pharmaceutical company focuses on the development of oral sustained and controlled release drug products. The company manufactures and develops generic drugs with Abbreviated New Drug Applications (ANDA) and branded drugs with New Drug Application (NDA) for the treatment of pain, obesity, hypertension, depression, infection and allergy, among others. Elite also has a pipeline of abuse-deterrent opioids for the treatment of chronic pain. The company uses its proprietary ART (abuse-deterrent technology) platform to develop and manufacture oral, controlled-release drugs. Elite is headquartered in Northvale, New Jersey, the US.

Elite Pharmaceuticals Inc (ELTP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Elite Pharma Acquires Trimipramine ANDA from Mikah Pharma 11
Elite Pharma Acquires Thirteen Abbreviated New Drug Application from Mikah Pharma 12
Partnerships 13
Elite Pharma Amends Co-Development and Licensing Agreement with SunGen Pharma 13
Elite Pharma Enters into Co-Development and Licensing Agreement with SunGen Pharma 14
Licensing Agreements 15
Elite Pharma Enters into Licensing Agreement with Glenmark Pharma 15
Glenmark Pharma Enters into Licensing Agreement with Elite Pharma 16
Elite Pharma Enters into Licensing Agreement with Epic Pharma for Abuse-Deterrent ELI-200 17
Elite Pharma Enters Into Licensing Agreement With Epic Pharma For Twelve Generic Products 18
Equity Offering 19
Elite Pharma to Raise USD40 Million in Private Placement of Shares 19
Elite Pharma to Raise Funds through Private Placement of Shares 20
Elite Pharma Announces Private Placement of Shares for USD40 Million 21
Elite Pharma Announces Private Placement Of Preferred Stock For US$5 Million 22
Elite Pharmaceuticals Inc – Key Competitors 23
Elite Pharmaceuticals Inc – Key Employees 24
Elite Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 09, 2018: Elite Pharmaceuticals reports financial results for the first quarter of fiscal year 2019 ended June 30, 2018 26
Jun 14, 2018: Elite Pharmaceuticals Announces Financial Results for the Fiscal Year Ended March 31, 2018 27
Feb 09, 2018: Elite Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2018 Ended December 31, 2017 28
Nov 09, 2017: Elite Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2018 Ended September 30, 2017 29
Aug 09, 2017: Elite Pharmaceuticals Reports Financial Results For The First Quarter Of Fiscal Year 2018 Ended June 30, 2017 30
Jun 14, 2017: Elite Pharmaceuticals, Reports Financial Results for the Fiscal Year Ended March 31, 2017 and Provides Conference Call Information 31
Feb 09, 2017: Elite Pharmaceuticals Reports Results For Third Quarter Of Fiscal Year 2017 32
Corporate Communications 33
Aug 07, 2018: Elite Pharmaceuticals appoints Aqeel A. Fatmi to its Board of Directors 33
Product News 34
Oct 24, 2018: Elite Pharmaceuticals reports positive results from a pivotal bioequivalence study 34
08/30/2017: Elite Pharmaceuticals to Present ELI-200 (SequestOx) Data at PAINWeek 2017 National Conference 35
07/07/2017: Elite Pharmaceuticals Reports Topline Results from a Pivotal Fed Bioequivalence Study for SequestOx 36
05/25/2017: Elite Pharmaceuticals SequestOx Study Results Expected In July 37
03/13/2017: Elite Pharmaceuticals Initiates Pivotal Bioequivalence Fed Study For Reformulated SequestOx 38
02/08/2018: Elite Pharmaceuticals and SunGen Pharma File ANDA 39
01/30/2018: Elite Pharmaceuticals Reports Positive Topline Results from SequestOx Pilot Study 40
Jan 17, 2017: Elite Pharmaceuticals Reports Positive Topline Results From A Pivotal Bioequivalence Study For A Generic OxyContin 41
Jan 10, 2018: Elite Pharmaceuticals Reports Positive Topline Results from Pivotal Bioequivalence Studies for an Extended-Release Generic 42
Product Approvals 43
Jan 23, 2017: Elite Reports On SequestOx FDA End-of-Review Meeting 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Elite Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Elite Pharma Acquires Trimipramine ANDA from Mikah Pharma 11
Elite Pharma Acquires Thirteen Abbreviated New Drug Application from Mikah Pharma 12
Elite Pharma Amends Co-Development and Licensing Agreement with SunGen Pharma 13
Elite Pharma Enters into Co-Development and Licensing Agreement with SunGen Pharma 14
Elite Pharma Enters into Licensing Agreement with Glenmark Pharma 15
Glenmark Pharma Enters into Licensing Agreement with Elite Pharma 16
Elite Pharma Enters into Licensing Agreement with Epic Pharma for Abuse-Deterrent ELI-200 17
Elite Pharma Enters Into Licensing Agreement With Epic Pharma For Twelve Generic Products 18
Elite Pharma to Raise USD40 Million in Private Placement of Shares 19
Elite Pharma to Raise Funds through Private Placement of Shares 20
Elite Pharma Announces Private Placement of Shares for USD40 Million 21
Elite Pharma Announces Private Placement Of Preferred Stock For US$5 Million 22
Elite Pharmaceuticals Inc, Key Competitors 23
Elite Pharmaceuticals Inc, Key Employees 24
Elite Pharmaceuticals Inc, Subsidiaries 25

List of Figures
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Elite Pharmaceuticals Inc (ELTP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Haworth, Inc.:企業の戦略・SWOT・財務分析
    Haworth, Inc. - Strategy, SWOT and Corporate Finance Report Summary Haworth, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • BioTime Inc (BTX):製薬・医療:M&Aディール及び事業提携情報
    Summary BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also develo …
  • ABB Ltd (ABBN):企業の財務・戦略的SWOT分析
    ABB Ltd (ABBN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • DIRECT Pojistovna, a.s.:企業の戦略・SWOT・財務分析
    DIRECT Pojistovna, a.s. - Strategy, SWOT and Corporate Finance Report Summary DIRECT Pojistovna, a.s. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BioFire Diagnostics LLC:企業の製品パイプライン分析2018
    Summary BioFire Diagnostics LLC (BioFire Diagnostics), formerly Idaho Technology Inc, a subsidiary of bioMerieux SA, is a molecular diagnostics company that offers molecular biology products. The company offers solutions for healthcare providers, labs and customers. It provides respiratory, meningit …
  • Ajinomoto Co Inc (2802):企業の財務・戦略的SWOT分析
    Ajinomoto Co Inc (2802) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Vindhya Telelinks Ltd:企業の戦略・SWOT・財務情報
    Vindhya Telelinks Ltd - Strategy, SWOT and Corporate Finance Report Summary Vindhya Telelinks Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Nemus Bioscience Inc (NMUS):製薬・医療:M&Aディール及び事業提携情報
    Summary Nemus Bioscience Inc (Nemus Bioscience) is a life-science and biopharmaceutical company that offers discovering, developing and commercializing cannabinoid-based therapeutics. The company’s drug pipeline products include NB1111, NB1222, NB2111, NB2222 and Cannabinoid platform NB3111. Its can …
  • Famous Dave’s of America, Inc.:戦略・SWOT・企業財務分析
    Famous Dave's of America, Inc. - Strategy, SWOT and Corporate Finance Report Summary Famous Dave's of America, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Grohe AG:企業の戦略的SWOT分析
    Grohe AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Alexion Pharmaceuticals Inc (ALXN):企業の財務・戦略的SWOT分析
    Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Carlisle Companies Inc:企業の戦略・SWOT・財務情報
    Carlisle Companies Inc - Strategy, SWOT and Corporate Finance Report Summary Carlisle Companies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Federal Electricity & Water Authority:企業の戦略的SWOT分析
    Federal Electricity & Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Informa plc:企業の戦略・SWOT・財務分析
    Informa plc - Strategy, SWOT and Corporate Finance Report Summary Informa plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • TDK Corporation:企業の戦略・SWOT・財務情報
    TDK Corporation - Strategy, SWOT and Corporate Finance Report Summary TDK Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • University College London Hospitals NHS Foundation Trust:企業の戦略的SWOT分析
    University College London Hospitals NHS Foundation Trust - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key …
  • Bauer AG (B5A):企業の財務・戦略的SWOT分析
    Bauer AG (B5A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Teachers Mutual Bank Ltd:企業の戦略的SWOT分析
    Teachers Mutual Bank Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • SANUWAVE Health Inc (SNWV):企業の財務・戦略的SWOT分析
    Summary Sanuwave Health Inc (Sanuwave), formerly Rub Music Enterprises Inc, is a medical device company that develops and commercializes noninvasive biological response activating devices. The company's products portfolio include dermapace, which is used in the treatment of chronic and acute conditi …
  • Immupharma Plc (IMM):製薬・医療:M&Aディール及び事業提携情報
    Summary ImmuPharma Plc (ImmuPharma) develops novel drugs for the treatment of serious medical conditions with unmet medical need. ImmuPharma develops drugs for the treatment of lupus, cancer, moderate to severe pain, highly resistant hospital-acquired infections such as methicillin-resistant staphyl …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆